Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Receivables (2022 - 2025)

Spero Therapeutics (SPRO) has disclosed Receivables for 4 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables fell 95.38% year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Sep 2025, down 95.38%, and an annual FY2024 reading of $52.5 million, up 3.51% over the prior year.
  • Receivables was $2.5 million for Q3 2025 at Spero Therapeutics, down from $26.9 million in the prior quarter.
  • Across five years, Receivables topped out at $55.5 million in Q2 2024 and bottomed at $1.1 million in Q4 2022.
  • Average Receivables over 4 years is $35.7 million, with a median of $50.7 million recorded in 2023.
  • The sharpest move saw Receivables surged 4576.85% in 2023, then crashed 95.38% in 2025.
  • Year by year, Receivables stood at $1.1 million in 2022, then soared by 4576.85% to $50.7 million in 2023, then rose by 3.51% to $52.5 million in 2024, then crashed by 95.31% to $2.5 million in 2025.
  • Business Quant data shows Receivables for SPRO at $2.5 million in Q3 2025, $26.9 million in Q2 2025, and $24.3 million in Q1 2025.